Literature DB >> 28889074

Interaction between FKBP5 gene and childhood trauma on psychosis, depression and anxiety symptoms in a non-clinical sample.

Marta de Castro-Catala1, Elionora Peña1, Thomas R Kwapil2, Sergi Papiol3, Tamara Sheinbaum4, Paula Cristóbal-Narváez4, Sergi Ballespí4, Neus Barrantes-Vidal5, Araceli Rosa6.   

Abstract

BACKGROUND: Childhood trauma has been associated with a heightened risk for presenting clinical and non-clinical psychopathology in adulthood. Genes related with the stress response, such as the FK506 binding protein 51 (FKBP5), are plausible candidates moderating the effects of childhood trauma on the emergence of such symptoms later on. The present study aimed to explore the moderating role of FKBP5 genetic variability on the association of different types of childhood trauma with subclinical psychosis, depression and anxiety in a non-clinical sample.
METHODS: Schizotypy, psychotic-like experiences, depression and anxiety symptoms and childhood trauma were assessed in 808 young adults. Two FKBP5 haplotypic blocks were detected: block 1 (rs3800373 - rs9296158 - rs1360780) and block 2 (rs9470080 - rs4713916). Subjects were classified in two groups according to whether they carried or not the risk haplotype previously described in the literature (block 1: CAT and block 2: TA). Linear regression analyses were used to study (i) the main effects of childhood trauma and FKBP5 haplotype blocks and (ii) their interaction effects on the mentioned forms of psychopathology.
RESULTS: All childhood trauma scales, except sexual abuse, were associated with schizotypy, psychotic-like experiences, depression and anxiety symptoms. None of the analysed symptoms was associated with the main effects of FKBP5 genetic variability. However an interaction effect between block 1 and physical abuse was observed on anxiety, with lower scores in CAT carriers. This effect was driven by SNP 1 and 2. Moreover, an interaction effect between block 2 and physical abuse was identified on the variables tapping depressive and anxiety symptoms. Specifically, non-TA carrier subjects who were exposed to physical abuse were found to be at higher risk for depressive and anxiety symptoms. These effects were driven by SNP 5. No interaction effect was observed for the other variables.
CONCLUSIONS: Our data suggest that exposure to childhood physical abuse may increase the risk for sub-clinical depressive and anxiety symptoms depending on FKBP5 genetic variability. Further research is needed to better elucidate the role of FKBP5 on mental health in clinical and non-clinical cohorts.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety; Childhood trauma; Depression; FKBP5 gene; Gene-environment interaction; Psychotic-like experiences; Schizotypy

Mesh:

Substances:

Year:  2017        PMID: 28889074     DOI: 10.1016/j.psyneuen.2017.08.024

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  8 in total

Review 1.  Current Knowledge on Gene-Environment Interactions in Personality Disorders: an Update.

Authors:  Andrea Bulbena-Cabre; Anahita Bassir Nia; M Mercedes Perez-Rodriguez
Journal:  Curr Psychiatry Rep       Date:  2018-08-09       Impact factor: 5.285

Review 2.  Gene-Environment Interactions in Psychiatry: Recent Evidence and Clinical Implications.

Authors:  Rashelle J Musci; Jura L Augustinavicius; Heather Volk
Journal:  Curr Psychiatry Rep       Date:  2019-08-13       Impact factor: 5.285

3.  The Impact of the FKBP5 Gene Polymorphisms on the Relationship between Traumatic Life Events and Psychotic-Like Experiences in Non-Clinical Adults.

Authors:  Filip Stramecki; Dorota Frydecka; Łukasz Gawęda; Katarzyna Prochwicz; Joanna Kłosowska; Jerzy Samochowiec; Krzysztof Szczygieł; Edyta Pawlak; Elżbieta Szmida; Paweł Skiba; Andrzej Cechnicki; Błażej Misiak
Journal:  Brain Sci       Date:  2021-04-28

4.  Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study).

Authors:  Juan P Sanabria-Mazo; Carlos G Forero; Paula Cristobal-Narváez; Carlos Suso-Ribera; Azucena García-Palacios; Ariadna Colomer-Carbonell; Adrián Pérez-Aranda; Laura Andrés-Rodríguez; Lance M McCracken; Francesco D'Amico; Pere Estivill-Rodríguez; Bernat Carreras-Marcos; Antonio Montes-Pérez; Olga Comps-Vicente; Montserrat Esteve; Mar Grasa; Araceli Rosa; Antonio I Cuesta-Vargas; Michael Maes; Xavier Borràs; Silvia Edo; Antoni Sanz; Albert Feliu-Soler; Juan R Castaño-Asins; Juan V Luciano
Journal:  BMJ Open       Date:  2020-07-23       Impact factor: 2.692

5.  Corticosteroid-binding-globulin (CBG)-deficient mice show high pY216-GSK3β and phosphorylated-Tau levels in the hippocampus.

Authors:  José Gulfo; Joana Pérez de San Román; Angelo Ledda; Felix Junyent; María J Ramírez; Francisco J Gil-Bea; Montserrat Esteve; Mar Grasa
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

6.  The Interaction Between POMC rs2071345 Polymorphism and Alcohol Dependence in Anxiety Symptoms Among Chinese Male Problem Drinkers.

Authors:  Liuzhi Hong; Lutong Wen; Michelle Niculescu; Fan Zhou; Yang Zou; Guanghui Shen; Wei Wang; Yanlong Liu; Yu-Hsin Chen; Fan Wang; Li Chen
Journal:  Front Psychiatry       Date:  2022-05-03       Impact factor: 4.157

7.  Influence of FKBP5 Variants and Childhood Trauma on Brain Volume in Non-clinical Individuals.

Authors:  Aeran Kwon; Sungkean Kim; Hyeonjin Jeon; Hyun Seo Lee; Seung-Hwan Lee
Journal:  Front Behav Neurosci       Date:  2021-06-03       Impact factor: 3.558

8.  Effects of childhood trauma experience and COMT Val158Met polymorphism on brain connectivity in a multimodal MRI study.

Authors:  Tian Tian; Jia Li; Guiling Zhang; Jian Wang; Dong Liu; Changhua Wan; Jicheng Fang; Di Wu; Yiran Zhou; Wenzhen Zhu
Journal:  Brain Behav       Date:  2020-09-30       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.